Andere Sprachen Immunome, Inc.

Aktien

A2QD9D

US45257U1088

IMNM

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 06.05.2024			% 5 Tage	% 1. Jan.
15,46 ^USD	-1,84 %		+11,87 %	+44,49 %

02.05.	Immunome, Inc. ernennt Kinney Horn zum Chief Business Officer	CI
30.04.	IMMUNOME, INC. : JPMorgan Chase bekräftigt seine Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Immunome Appoints Kinney Horn as Chief Business Officer	02.05.
Immunome, Inc. Appoints Kinney Horn as Chief Business Officer	02.05.
Immunome Appoints Sandra M. Swain to Board of Directors	25.04.
Immunome, Inc. Appoints Sandra M. Swain to Board of Directors	25.04.
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research Annual Meeting	08.04.
Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting	05.04.
Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets	28.03.
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala	26.03.
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome	26.03.
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	25.03.
Immunome to Participate in the Leerink Partners Global Biopharma Conference	07.03.
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	04.03.
Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference	01.03.
Immunome Recognizes Ayala Pharmaceuticals Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	21.02.
Immunome Recognizes Ayala Pharmaceuticals’ Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20.02.
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors	20.02.
Immunome Closes $230 Million Public Offering	16.02.
Immunome Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	16.02.
Immunome Prices Stock Offering at $20 a Share	14.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Immunome, Inc.

Aktien

A2QD9D

US45257U1088

IMNM

Andere Sprachen

Filter